Pancreatic Cancer Research

ResearcherNantong UniversityActive in the last 2 years

Guoxiong Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1824-3329; OpenAlex author ID A5090164349, A5102016401. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2015: 4 papers · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 12

  1. [Retracted] Inhibition of 5‑lipoxygenase triggers apoptosis in pancreatic cancer cells. Co-author DOI 10.3892/or.2024.8853↗
  2. Association of ACP5 with the tumor immune microenvironment and its role in cell proliferation and metastasis in pancreatic cancer. Last author PMID 38074824↗
  3. A super-enhancer controls TGF- β signaling in pancreatic cancer through downregulation of TGFBR2. Last author DOI 10.1016/j.cellsig.2019.109470↗
  4. LncRNA SNHG12 contributes proliferation, invasion and epithelial-mesenchymal transition of pancreatic cancer cells by absorbing miRNA-320b. First author DOI 10.1042/bsr20200805↗
  5. Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma. Last author DOI 10.3892/etm.2016.3968↗
  6. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Co-author DOI 10.1016/j.canlet.2016.01.026↗
  7. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2016.07.015↗
  8. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. Co-author DOI 10.1016/j.yexmp.2016.08.001↗
  9. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11010-015-2535-7↗
  10. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s13277-015-3625-6↗
  11. Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells. Last author DOI 10.3892/mmr.2015.3960↗
  12. Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3650↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wei Cao · 3 shared papers, 2016–2025 · strength 0.57
  2. Xiaoling Ding · 4 shared papers, 2015–2025 · strength 0.45
  3. Xiaolin Zhu · 2 shared papers, 2020–2023 · strength 0.30
  4. Jianbo Shen · 2 shared papers, 2020–2023 · strength 0.30
  5. Hong Zhang · 1 shared paper, 2025 · strength 0.28
  6. Chunhua Wan · 5 shared papers, 2015–2016 · strength 0.25
  7. Mingbing Xiao · 3 shared papers, 2016–2020 · strength 0.21
  8. Tingting Zhang · 1 shared paper, 2023 · strength 0.19
  9. Gong Chen · 3 shared papers, 2015–2017 · strength 0.17
  10. Ji Li · 3 shared papers, 2015–2017 · strength 0.16
  11. Ying Xiao · 3 shared papers, 2016 · strength 0.16
  12. Xiaohong Li · 2 shared papers, 2016 · strength 0.11
  13. Yihui Fan · 1 shared paper, 2020 · strength 0.10
  14. Renfang Mao · 1 shared paper, 2020 · strength 0.10
  15. Erhao Zhang · 1 shared paper, 2020 · strength 0.10
  16. Xiaorong Liu · 2 shared papers, 2015 · strength 0.09
  17. Hongyan Zhu · 1 shared paper, 2017 · strength 0.07
  18. Bo Jiang · 1 shared paper, 2015 · strength 0.06
  19. Xiaorong Zhou · 1 shared paper, 2015 · strength 0.06
  20. Hong Zhang · 1 shared paper, 2015 · strength 0.06
  21. Aiguo Shen · 1 shared paper, 2016 · strength 0.05
  22. Haifeng Zhang · 1 shared paper, 2015 · strength 0.05
  23. Liang Wang · 1 shared paper, 2015 · strength 0.04
  24. Yixin Zhang · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.